111 related articles for article (PubMed ID: 27061562)
1. The role of tyrosine kinase inhibitors in the treatment of renal cell carcinoma with brain metastases.
Aytekin A; Ciltas A; Sahinli H; Benekli M
J BUON; 2016; 21(1):281-2. PubMed ID: 27061562
[No Abstract] [Full Text] [Related]
2. Re: E. Jason Abel, Stephen H. Culp, Nizar M. Tannir, et al. Primary tumor response to targeted agents in patients with metastatic renal cell carcinoma. Eur Urol 2011;59:10-5.
Ozcan MF; Canda AE; Dizdar O; Altinova S; Akbulut Z; Balbay MD
Eur Urol; 2011 Jun; 59(6):e34. PubMed ID: 21398023
[No Abstract] [Full Text] [Related]
3. Against: The case for cytoreductive nephrectomy for the management of metastatic renal cell carcinoma.
Carver BS
J Urol; 2009 Sep; 182(3):833-4. PubMed ID: 19616224
[No Abstract] [Full Text] [Related]
4. Influence of Prior Tyrosine Kinase Inhibitor on Survival for Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab or Cabozantinib: Data from a Literature-based Meta-analysis.
Roviello G; Generali D
Eur Urol; 2017 Dec; 72(6):1027-1028. PubMed ID: 28760645
[No Abstract] [Full Text] [Related]
5. [Tyrosine kinase inhibitor as adjuvant treatment of renal cell carcinoma: 1 versus 3].
Penel N
Bull Cancer; 2017 Sep; 104(9):705-706. PubMed ID: 28760312
[No Abstract] [Full Text] [Related]
6. Metastatic renal cell carcinoma: role of mammalian target of rapamycin inhibitors.
Bukowski RM
Clin Genitourin Cancer; 2007 Sep; 5(6):359-61. PubMed ID: 17956708
[No Abstract] [Full Text] [Related]
7. Fulminant acneiform eruptions after administration of dovitinib in a patient with renal cell carcinoma.
Hsiao YW; Lin YC; Hui RC; Yang CH
J Clin Oncol; 2011 Apr; 29(12):e340-1. PubMed ID: 21263088
[No Abstract] [Full Text] [Related]
8. Exceptional Response to Cabozantinib of Rapidly Evolving Brain Metastases of Renal Cell Carcinoma: A Case Report and Review of the Literature.
Ciccarese C; Iacovelli R; Mosillo C; Tortora G
Clin Genitourin Cancer; 2018 Oct; 16(5):e1069-e1071. PubMed ID: 30005936
[No Abstract] [Full Text] [Related]
9. [Resistance to tyrosine kinase inhibitors in renal cell carcinoma].
Miyake H; Fujisawa M
Nihon Rinsho; 2012 Nov; 70 Suppl 8():331-5. PubMed ID: 23513861
[No Abstract] [Full Text] [Related]
10. Pazopanib: an oral multitargeted tyrosine kinase inhibitor for use in renal cell carcinoma.
LaPlant KD; Louzon PD
Ann Pharmacother; 2010 Jun; 44(6):1054-60. PubMed ID: 20407031
[TBL] [Abstract][Full Text] [Related]
11. Severe epistaxis with tyrosine kinase inhibitors.
Hall PS; Kancherla K; Sastry PS; Brown JE
Clin Oncol (R Coll Radiol); 2008 May; 20(4):318-9. PubMed ID: 18353621
[No Abstract] [Full Text] [Related]
12. A phase II study of GW786034 using a randomized discontinuation design in patients with locally recurrent or metastatic clear-cell renal cell carcinoma.
Hutson TE; Bukowski RM
Clin Genitourin Cancer; 2006 Mar; 4(4):296-8. PubMed ID: 16729915
[No Abstract] [Full Text] [Related]
13. Update on the use of mTOR inhibitors in renal cell carcinoma.
Rini BI
Clin Adv Hematol Oncol; 2008 Oct; 6(10):722-4. PubMed ID: 18997660
[No Abstract] [Full Text] [Related]
14. Sorafenib in renal cell carcinoma.
Arranz JÁ; Climent MÁ; González-Larriba JL; León L; Maroto JP
Crit Rev Oncol Hematol; 2011 Nov; 80(2):314-22. PubMed ID: 21419641
[TBL] [Abstract][Full Text] [Related]
15. Surgical resection does not improve survival in patients with renal metastases to the pancreas in the era of tyrosine kinase inhibitors.
Santoni M; Conti A; Partelli S; Porta C; Sternberg CN; Procopio G; Bracarda S; Basso U; De Giorgi U; Derosa L; Rizzo M; Ortega C; Massari F; Iacovelli R; Milella M; Di Lorenzo G; Buti S; Cerbone L; Burattini L; Montironi R; Santini D; Falconi M; Cascinu S
Ann Surg Oncol; 2015; 22(6):2094-100. PubMed ID: 25472645
[TBL] [Abstract][Full Text] [Related]
16. [Drug treatment of metastatic renal cell carcinoma].
Rafiyan MR; Jäger E
Dtsch Med Wochenschr; 2013 Aug; 138(31-32):1567-70. PubMed ID: 23836159
[No Abstract] [Full Text] [Related]
17. Continuing response to subsequent treatment lines with tyrosine kinase inhibitors in an adolescent with metastatic renal cell carcinoma.
De Pasquale MD; Pessolano R; Boldrini R; Ilari I; Donfrancesco A; Cortesi E; Jenkner A
J Pediatr Hematol Oncol; 2011 Jul; 33(5):e176-9. PubMed ID: 21552143
[TBL] [Abstract][Full Text] [Related]
18. Tyrosine kinase inhibitors reprogramming immunity in renal cell carcinoma: rethinking cancer immunotherapy.
Aparicio LMA; Fernandez IP; Cassinello J
Clin Transl Oncol; 2017 Oct; 19(10):1175-1182. PubMed ID: 28409322
[TBL] [Abstract][Full Text] [Related]
19. [New treatment of metastatic renal cancer. The Danish Society of Clinical Oncology].
Sengeløv L; Geertsen PF;
Ugeskr Laeger; 2007 Mar; 169(12):1117. PubMed ID: 17394828
[No Abstract] [Full Text] [Related]
20. Do tyrosine kinase inhibitors lose favor in treatment of first-line metastatic renal cell carcinoma?
Yaman S; Bilgin B; Şendur MA; Hızal M; Akıncı MB; Yalçın B
Future Oncol; 2019 Mar; 15(9):925-927. PubMed ID: 30854890
[No Abstract] [Full Text] [Related]
[Next] [New Search]
